Newsfeeds Archive - Spark Newswire

1 minute read

Korro FY23 EPS $(53.08) Vs $(227.42) YoY

March 26, 4:16 PM

Full Year 2023 Financial Results:Cash Position: Cash, cash equivalents and short-term investments were $166.1 million as of December 31, 2023, compared to $55.2 million as of December 31, 2022. Korro expects that its

KRRO

2 minute read

Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

February 13, 11:09 AM

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday.

ASPN

3 minute read

Korro Bio Highlights Data For Its Lead Program In Alpha-1 Antitrypsin Deficiency And Progress Across Its RNA Editing Portfolio

By Benzinga Newsdesk

January 18, 9:12 AM

KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in non-human primates

KRRO

3 minute read

Korro Announces Selection Of Its First Development Candidate For The Potential Treatment Of Alpha-1 Antitrypsin Deficiency

By Benzinga Newsdesk

December 7, 9:10 AM

KRRO-110 is the first RNA editing oligonucleotide candidate from Korro's proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT) protein

KRRO

1 minute read

Why Newly Listed Korro Bio Shares Are Gaining Today

By Vandana Singh

December 4, 3:34 PM

H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.

ALNY